Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.60 |
| ▸ | TGFBR1 | P36897 | 16/20 | 0.55 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.45 |
| ▸ | SMAD2 | Q15796 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030130 | 0.80 | TGFBR1 (0.63) | MAPK14TGFBR1 | |
| SCHEMBL12373227 | 0.80 | MAPK14 (0.71) | MAPK14TGFBR1BMPR1ASMAD2DYRK1A | |
| SCHEMBL4031433 | 0.78 | TGFBR1 (0.54) | MAPK14TGFBR1 | |
| SCHEMBL4032155 | 0.77 | TGFBR1 (0.44) | MAPK14TGFBR1 | |
| SCHEMBL38654884 | 0.77 | TGFBR1 (0.56) | MAPK14TGFBR1BMPR1ASMAD2DYRK1A | |
| SCHEMBL4038621 | 0.75 | TGFBR1 (0.40) | MAPK14TGFBR1 | |
| SCHEMBL6881791 | 0.75 | TGFBR1 (0.67) | MAPK14TGFBR1BMPR1ASMAD2 | |
| SCHEMBL12373289 | 0.75 | MAPK14 (1.00) | MAPK14TGFBR1DYRK1A | |
| SCHEMBL4029863 | 0.74 | MAPK14 (0.47) | MAPK14TGFBR1 | |
| SCHEMBL4032592 | 0.73 | TGFBR1 (0.55) | MAPK14TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542994-B1 | NOVEL OXAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITOR | PFIZER PROD INC (US) | 2009-04-29 | — | — | EP | claimed |
| EP-1542994-B1 | NOVEL OXAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITOR | PFIZER PROD INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-7273936-B2 | Oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2007-09-25 | — | — | US | disclosed |
| EP-1542994-A1 | NOVEL TRIAZOLE AND OXAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITOR | Pfizer Products Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040110797-A1 | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
| WO-2004026863-A1 | NOVEL OXAZOLE AND THIAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110797-A1 | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | TGFBR1, TGFBR2, SMAD3 | MAPK14 319/4885TGFBR1 1/4885BMPR1A 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.